Cell surface transporters play a key role in human health and disease, both through their impact on drug disposition and as therapeutic targets in their own right. This third meeting in the series will feature talks on transporter structural biology, the impact of transporters on ADME and biodistribution, transporters as therapeutic targets and other aspects of transporters relevant to drug discovery and development
The full programme will be announced in due course.
Genomics of transporters - informing drug development
Kathy Giacomini, UCSF, USA
Graham Belfield, AstraZeneca, Switzerland
Jeremy Burrows, Medicines for Malaria Venture, Switzerland
New model for P-gp and CNS at the blood-brain barrier
Holger Fischer, Roche, Switzerland
Strategies for the pharmacological modulation of ABC transporters
Christopher Koth, Genentech, USA
Transporter structural biology
Kaspar Locher, ETH Zurich, Switzerland
Transporter PBPK modelling and DDI
Venkatesh Reddy, AstraZeneca, UK
PBPK of transporter-mediated hepatic disposition using the imaging biomarker gadoxetate
Daniel Scotcher, University of Manchester, UK
The evolution of transporters in drug discovery
Anna-Lena Ungell, UCB, UK
14/15 Belgrave Square
Tel: +44 (0)20 7598 1561
Read our event booking terms and conditions
An abstract of maximum one A4 page or 300 words, indicating title, authors and preference for presentation option (oral or poster) should be sent to firstname.lastname@example.org by Monday 24 February 2020 with the subject line “Transporters – abstract submission”. An abstract template can be downloaded here.
An exhibition will take place alongside the conference during refreshment breaks for companies and related organisations who may wish to exhibit. For further information and prices, please email email@example.com. Spaces are limited and will be allocated on a first come, first served basis.